Companies › GenSight Biologics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GS010 (lenadogene nolparvovec, Lumevoq) AAV5-delivered ND4 gene replacement therapy for LHON | ND4 | Phase 2 | Leber Hereditary Optic Disease | May 2028 |
| GS030-DP Recombinant adeno-associated viral vector (rAAV2.7m8) delivering ChrimsonR-tdTomato gene f | CHRM5 | Phase 1 | Non-syndromic Retinitis Pigmentosa | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03326336 | GS030-DP | Phase 1 | Non-syndromic Retinitis Pigmentosa | Ophthalmology | Oct 2027 |
| NCT07303296 | GS010 (lenadogene nolparvovec, Lumevoq) | Phase 2 | Leber Hereditary Optic Disease | Ophthalmology | May 2028 |
jCyte NovaSight Emmecell Price Vision Group NexThera
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.